NewAmsterdam Pharma Co N.V.·4

Mar 10, 8:58 PM ET

LANGE LOUIS G 4

4 · NewAmsterdam Pharma Co N.V. · Filed Mar 10, 2026

Research Summary

AI-generated summary of this filing

Updated

NewAmsterdam (NAMS) Director Louis G. Lange Sells Shares, Exercises Options

What Happened

  • Director Louis G. Lange sold 28,186 NewAmsterdam (NAMS) shares in an open-market disposition on 2026-03-06 for a weighted average price of $29.41, generating about $828,950.
  • On 2026-03-09 he exercised in-the-money options to acquire 44,619 shares at a strike price of $11.50 per share (cost ≈ $513,119). A corresponding derivative disposition at $0.00 was also reported for the same 44,619-share lot (see Context below).
  • The sale is a routine disposition; the option exercise resulted in a net increase of 16,433 shares held by the insider (44,619 acquired − 28,186 sold).

Key Details

  • Transaction dates and prices:
    • 2026-03-06: Sale (open market) 28,186 shares @ weighted avg $29.41 (range $29.03–$29.68) — proceeds ≈ $828,950. (Footnote F1)
    • 2026-03-09: Exercise of options to acquire 44,619 shares @ $11.50 — cost ≈ $513,119; derivative disposition reported at $0.00.
  • Net effect: +16,433 shares (44,619 acquired − 28,186 sold). Net cash received ≈ $315,831 (proceeds minus exercise cost).
  • Shares are held directly by LGLange III Trust DTD10 for the benefit of the reporting person (Footnote F2). The filing does not list the reporter’s total post-transaction share count in the provided excerpt.
  • Filing: Reported on 2026-03-10 for trades dated 2026-03-06 and 2026-03-09. Filing appears timely (not indicated as late).

Context

  • The 3/9 entries reflect an option exercise: the reporting person paid the strike price ($11.50) to acquire shares; the $0.00 derivative disposition indicates cancellation/conversion of the option instrument rather than an open-market sale of the newly acquired shares.
  • Sales can be routine (liquidity/tax reasons); exercises show the insider added shares to their position. This summary is factual and does not speculate on motivation.

Insider Transaction Report

Form 4
Period: 2026-03-06
Transactions
  • Sale

    Ordinary Shares

    [F1][F2]
    2026-03-06$29.41/sh28,186$828,9500 total(indirect: See footnote)
  • Exercise of In-Money

    Ordinary Shares

    2026-03-09$11.50/sh+44,619$513,11954,979 total
  • Exercise of In-Money

    Warrant (right to buy)

    2026-03-0944,6190 total
    Exercise: $11.50From: 2022-12-22Exp: 2027-11-23Ordinary Shares (44,619 underlying)
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F2]The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.
Signature
/s/ Louise Kooij by Power of Attorney from Louis G. Lange|2026-03-10

Documents

1 file
  • 4
    ownership.xmlPrimary

    4